| Unique ID issued by UMIN | UMIN000054119 |
|---|---|
| Receipt number | R000060702 |
| Scientific Title | Predicting neoadjuvant chemotherapy response of muscle-invasive bladder cancer using patient-derived zebrafish xenograft model: multi-institutional prospective study |
| Date of disclosure of the study information | 2024/05/01 |
| Last modified on | 2024/04/11 13:36:16 |
Predicting neoadjuvant chemotherapy response of muscle-invasive bladder cancer using patient-derived zebrafish xenograft model: multi-institutional prospective study
Bladder cancer patient-derived zebrafish xenograft model
Predicting neoadjuvant chemotherapy response of muscle-invasive bladder cancer using patient-derived zebrafish xenograft model: multi-institutional prospective study
Bladder cancer patient-derived zebrafish xenograft model
| Japan |
Muscle-invasive bladder cancer
| Urology |
Malignancy
YES
Aim of this study is to evaluate response to platinum-based neoadjuvant chemotherapy (NAC) of muscle-invasive bladder cancer (MIBC) by trans-urethral resected bladder specimens transplanted zebrafish xenograft model and compared with pathological and histological diagnosis of radical cystectomy specimens after NAC. And near future we will apply zPDX system to clinical field for precision medicine before treating MIBC with platinum-based neoadjuvant chemotherapy.
Others
Gene expression/mutation analysis of bladder cancer tissue collected transurethrally and residual bladder cancer tissue in radical cystectomy specimens and comparative study of anticancer drug reactivity were conducted to find targets for platinum-based chemotherapy resistant cancer cells.
Exploratory
Bladder cancer tissue collected transurethrally before NAC from a patient scheduled to undergo radical cystectomy after neoadjuvant chemotherapy (NAC) with a platinum-based anticancer drug for muscle-invasive bladder cancer. Transplant into zebrafish and evaluate the effectiveness of platinum-based anticancer drugs. The results will be compared with the pathological evaluation of the total cystectomy specimen after NAC, and the concordance rate will be the primary endpoint.
Observational
| Not applicable |
| Not applicable |
Male and Female
1. New case of muscle-invasive bladder cancer
2. Tumors of sufficient amount of transurethral resection
3. Patients who receive neoadjuvant platinum-based chemotherapy
4. Patients who receive radical cystectomy
5. Patients with available clinical and pathological information
6. Patients who consented.
Patients who are not appropriate to enter the clinical study.
100
| 1st name | TAKAHIRO |
| Middle name | |
| Last name | INOUE |
Mie University Graduate School of Medicine
Nephro-Urologic Surgery and Andrology
514-8507
2-174 Edobashi Tsu Mie
0592315026
tinoue28@med.mie-u.ac.jp
| 1st name | Yusuke |
| Middle name | |
| Last name | Sugino |
Mie University Graduate School of Medicine
Nephro-Urologic Surgery and Andrology
514-8507
2-174 Edobasih Tsu Mie
0592315026
tinoue28@med.mie-u.ac.jp
Mie University Graduate School of Medicine
Grants-in-Aid for Scientific Research
Other
the Clinical Research Ethics Review Committee of Mie University Hospital
2-174 Edobasih Tsu Mie
059-231-5045
kk-sien@med.mie-u.ac.jp
NO
| 2024 | Year | 05 | Month | 01 | Day |
Unpublished
Preinitiation
| 2024 | Year | 04 | Month | 11 | Day |
| 2024 | Year | 05 | Month | 01 | Day |
| 2028 | Year | 12 | Month | 31 | Day |
Patient information
Bladder cancer pathological information
Zebrafish xenograft successful rate
others
| 2024 | Year | 04 | Month | 11 | Day |
| 2024 | Year | 04 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060702